U.S. Senate Hearing: Oversight of the FDA's Foreign Drug Manufacturing Inspection Process
Celebrity Pictures > Archives > 2020 > June >
U.S. Senate Hearing: Oversight of the FDA's Foreign Drug Manufacturing Inspection Process (57 pictures)
View All Images- David Light, Founder and CEO of Valisure, listens during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- David Light, Founder and CEO of Valisure, listens during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Martin VanTrieste, President & Chief Executive Officer of CivicaRx, speaks via teleconference during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- David Light, Founder and CEO of Valisure, listens during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- David Light, Founder and CEO of Valisure, listens during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- United States Senator Ron Wyden (Democrat of Oregon) speaks via teleconference during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- United States Senator Ben Sasse (Republican of Nebraska) listens during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- David Light, Founder and CEO of Valisure, listens during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- David Light, Founder and CEO of Valisure, listens during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- United States Senator Ron Wyden (Democrat of Oregon) speaks via teleconference during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- David Light, Founder and CEO of Valisure, listens during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Mark Abdoo, Associate Commissioner for Global Policy and Strategy at the Food and Drug Administration (FDA) listens during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Douglas Throckmorton M.D., Deputy Director for Regulatory Programs at the Food and Drug Administration (FDA) speaks via teleconference during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Judith McMeekin, Associate Commissioner for Regulatory Affairs at the Food and Drug Administration (FDA), right, and Mark Abdoo, Associate Commissioner for Global Policy and Strategy at the Food and Drug Administration (FDA), listen during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Douglas Throckmorton M.D., Deputy Director for Regulatory Programs at the Food and Drug Administration (FDA) speaks via teleconference during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Judith McMeekin, Associate Commissioner for Regulatory Affairs at the Food and Drug Administration (FDA) listens during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Judith McMeekin, Associate Commissioner for Regulatory Affairs at the Food and Drug Administration (FDA), right, and Mark Abdoo, Associate Commissioner for Global Policy and Strategy at the Food and Drug Administration (FDA), listen during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- United States Senator John Cornyn (Republican of Texas) speaks during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Judith McMeekin, Associate Commissioner for Regulatory Affairs at the Food and Drug Administration (FDA), speaks during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Judith McMeekin, Associate Commissioner for Regulatory Affairs at the Food and Drug Administration (FDA), right, and Mark Abdoo, Associate Commissioner for Global Policy and Strategy at the Food and Drug Administration (FDA), listen during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Mark Abdoo, Associate Commissioner for Global Policy and Strategy at the Food and Drug Administration (FDA) listens during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- United States Senator Chuck Grassley (Republican of Iowa) listens during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- United States Senator Bob Menendez (Democrat of New Jersey) speaks via teleconference during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Judith McMeekin, Associate Commissioner for Regulatory Affairs at the Food and Drug Administration (FDA), right, and Mark Abdoo, Associate Commissioner for Global Policy and Strategy at the Food and Drug Administration (FDA), listen during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- United States Senator Tom Carper (Democrat of Delaware) speaks during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Hand sanitizer and Purell Hand Wipes sit on a table during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Judith McMeekin, Associate Commissioner for Regulatory Affairs at the Food and Drug Administration (FDA), right, and Mark Abdoo, Associate Commissioner for Global Policy and Strategy at the Food and Drug Administration (FDA), listen during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Douglas Throckmorton M.D., Deputy Director for Regulatory Programs at the Food and Drug Administration (FDA) speaks via teleconference as United States Senator Todd Young (Republican of Indiana) looks over notes during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- United States Senator Tom Carper (Democrat of Delaware) speaks during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Mary Denigan-Macauley, Ph.D., Director of Health Care at the United States Government Accountability Office, left, speaks via teleconference as Judith McMeekin, Associate Commissioner for Regulatory Affairs at the Food and Drug Administration (FDA), right, and Mark Abdoo, Associate Commissioner for Global Policy and Strategy at the Food and Drug Administration (FDA), listen during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- United States Senator Chuck Grassley (Republican of Iowa) adjusts his protective face mask prior to the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Judith McMeekin, Associate Commissioner for Regulatory Affairs at the Food and Drug Administration (FDA), right, and Mark Abdoo, Associate Commissioner for Global Policy and Strategy at the Food and Drug Administration (FDA), listen during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- David Light, Founder and CEO of Valisure, speaks during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Mark Abdoo, Associate Commissioner for Global Policy and Strategy at the Food and Drug Administration (FDA), speaks during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- United States Senator Steve Daines (Republican of Montana) speaks to a member of his staff during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- United States Senator Tom Carper (Democrat of Delaware), center, speaks to Judith McMeekin, Associate Commissioner for Regulatory Affairs at the Food and Drug Administration (FDA), right, and Mark Abdoo, Associate Commissioner for Global Policy and Strategy at the Food and Drug Administration FDA), before leaving the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Mark Abdoo, Associate Commissioner for Global Policy and Strategy at the Food and Drug Administration (FDA) listens during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- United States Senator John Cornyn (Republican of Texas) speaks during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- David Light, Founder and CEO of Valisure, speaks during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- United States Senator Chuck Grassley (Republican of Iowa) adjusts his protective face mask prior to the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Judith McMeekin, Associate Commissioner for Regulatory Affairs at the Food and Drug Administration (FDA), right, and Mark Abdoo, Associate Commissioner for Global Policy and Strategy at the Food and Drug Administration (FDA), listen during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Douglas Throckmorton M.D., Deputy Director for Regulatory Programs at the Food and Drug Administration (FDA) speaks via teleconference during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- United States Senator Chuck Grassley (Republican of Iowa) adjusts his protective face mask prior to the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Judith McMeekin, Associate Commissioner for Regulatory Affairs at the Food and Drug Administration (FDA), speaks during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Judith McMeekin, Associate Commissioner for Regulatory Affairs at the Food and Drug Administration (FDA), speaks during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Mark Abdoo, Associate Commissioner for Global Policy and Strategy at the Food and Drug Administration (FDA), listens during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Judith McMeekin, Associate Commissioner for Regulatory Affairs at the Food and Drug Administration (FDA), listens during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Mark Abdoo, Associate Commissioner for Global Policy and Strategy at the Food and Drug Administration (FDA), listens during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Mark Abdoo, Associate Commissioner for Global Policy and Strategy at the Food and Drug Administration (FDA) listens during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Judith McMeekin, Associate Commissioner for Regulatory Affairs at the Food and Drug Administration (FDA), speaks during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Mark Abdoo, Associate Commissioner for Global Policy and Strategy at the Food and Drug Administration (FDA), speaks during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Judith McMeekin, Associate Commissioner for Regulatory Affairs at the Food and Drug Administration (FDA), looks over notes during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- United States Senator John Thune (Republican of South Dakota) listens during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- United States Senator Chuck Grassley (Republican of Iowa) speaks during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- United States Senator Steve Daines (Republican of Montana) listens during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Douglas Throckmorton M.D., Deputy Director for Regulatory Programs at the Food and Drug Administration (FDA) speaks via teleconference during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia
- Judith McMeekin, Associate Commissioner for Regulatory Affairs at the Food and Drug Administration (FDA), speaks during the United States Senate Committee on Finance hearing regarding the inspection process of foreign drug manufacturing on Capitol Hill in Washington D.C., U.S., on Tuesday, June 2, 2020. Credit: Stefani Reynolds / CNP/AdMedia `